Treatment with axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated similar early efficacy as second-line therapy in real-world patients with relapsed/refractory large B-cell lymphoma (LBCL) compared with outcomes for...
Findings from an analysis of real-world patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma being treated with bispecific antibodies showed that epcoritamab-bysp (Epkinly)...